Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights March 18, 2019 • 8:00 AM EDT
Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder March 11, 2019 • 7:00 AM EDT
Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder March 1, 2019 • 5:41 PM EST
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion January 2, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement December 18, 2018 • 7:00 AM EST
